This little-known California-based biopharmaceutical stock can see its shares rally nearly 80% in the near term, according to Goldman Sachs.
Shares of the company’s stock were up more than 5% in trading Thursday on the back of Goldman analyst Paul Choi who issued a buy rating for this stock.
Subscribe to CNBC Pro to see which stock Goldman is predicting could rally nearly 80%.
Like getting these emails?Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas.